Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $6.63 million. The enterprise value is $2.04 million.
| Market Cap | 6.63M |
| Enterprise Value | 2.04M |
Important Dates
The next estimated earnings date is Friday, November 15, 2024, after market close.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 2.52 million shares outstanding. The number of shares has increased by 12.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.52M |
| Shares Change (YoY) | +12.40% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 23.59% |
| Owned by Institutions (%) | 15.68% |
| Float | 1.23M |
Valuation Ratios
The trailing PE ratio is 2.20.
| PE Ratio | 2.20 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.76 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.68 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.68
| Current Ratio | 3.68 |
| Quick Ratio | 3.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -150.25% and return on invested capital (ROIC) is -67.37%.
| Return on Equity (ROE) | -150.25% |
| Return on Assets (ROA) | -46.55% |
| Return on Capital (ROIC) | -67.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $3.01M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.66% in the last 52 weeks. The beta is 1.92, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.92 |
| 52-Week Price Change | +12.66% |
| 50-Day Moving Average | 2.78 |
| 200-Day Moving Average | 2.92 |
| Relative Strength Index (RSI) | 44.74 |
| Average Volume (20 Days) | 31,295 |
Short Selling Information
The latest short interest is 12,032, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 12,032 |
| Short Previous Month | 10,754 |
| Short % of Shares Out | 0.48% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 2.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | -553,000 |
| Operating Income | -7.51M |
| Pretax Income | 3.01M |
| Net Income | 3.01M |
| EBITDA | n/a |
| EBIT | -7.51M |
| Earnings Per Share (EPS) | $1.22 |
Balance Sheet
| Cash & Cash Equivalents | 4.59M |
| Total Debt | n/a |
| Net Cash | 4.59M |
| Net Cash Per Share | $1.82 |
| Equity (Book Value) | 8.78M |
| Book Value Per Share | 3.49 |
| Working Capital | 3.43M |
Cash Flow
| Operating Cash Flow | -11.45M |
| Capital Expenditures | n/a |
| Free Cash Flow | -11.45M |
| FCF Per Share | -$4.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.40% |
| Shareholder Yield | -12.40% |
| Earnings Yield | 45.35% |
| FCF Yield | -172.68% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 16, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | May 16, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |